APEN News and Press, Apollo Endosurgery Inc. From 11/12/21

AUSTIN, TX / ACCESSWIRE / November 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that management will participate in four upcoming investor conference events. ...

Apollo Endosurgery, Inc. (APEN) Q3 2021 Earnings Conference Call November 1, 2021 16:30 ET Company Participants Matt Kreps - Investor Relations Charles McKhann - Chief Executive Officer Jeff Black - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Mark...

AUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (Nasdaq:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, today announced financial results for the third quarter ended September 30, 2021 and recent corporat...

Study demonstrates high success rates, ease of use, and economic value in the treatment of GI defects AUSTIN, TX / ACCESSWIRE / November 1, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in minimally invasive medical devices for gastrointestinal and bariatric ...

AUSTIN, TX / ACCESSWIRE / October 27, 2021 / Apollo Endosurgery, Inc. ("Company" or "Apollo") (NASDAQ:APEN), a global leader in next-generation minimally invasive medical devices for gastrointestinal and bariatric procedures, today announced that the Company is scheduled to release its finan...

Trial Results Demonstrate ESG Procedure Offers Significant and Durable Weight Loss, with Improvements in Obesity-Related Health Conditions MERIT-Trial met its primary endpoints for safety and efficacy, with patients undergoing the Endoscopic Sleeve Gastroplasty (ESG) procedure achievin...

AUSTIN, TX / ACCESSWIRE / October 15, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the closing of its previously announced underwritten public offering. Apollo sold 9,...

AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today the pricing of its previously announced underwritten public offering. Apollo is sell...

AUSTIN, TX / ACCESSWIRE / October 12, 2021 / Apollo Endosurgery, Inc. ("Apollo") (NASDAQ:APEN), a global leader in less invasive medical devices for gastrointestinal and bariatric procedures, announced today that it intends to offer and sell shares of its common stock in an underwritten publ...

Revenue expected between $16.0 million and $16.4 million Third consecutive quarter of double-digit revenue growth; endoscopic suturing up over 30% Submitted a De Novo 510(k) Classification Request to FDA for Apollo ESG™ for weight loss and Apollo REVISE™ for prior ba...